G1 Therapeutics buy BiotechBee
Start price
24.12.22
/
50%
€5.09
Target price
31.12.25
€8.00
Performance (%)
-45.23%
End price
05.05.23
€2.79
Summary
This prediction ended on 05.05.23 with a price of €2.79. Massive losses of -45.23% were the result for the BUY prediction by BiotechBee. BiotechBee has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| G1 Therapeutics | -10.309% | -10.309% | 2.322% |
| iShares Core DAX® | -0.258% | 0.299% | 15.648% |
| iShares Nasdaq 100 | 2.964% | 4.660% | 32.001% |
| iShares Nikkei 225® | 1.217% | -2.160% | 6.668% |
| iShares S&P 500 | 1.732% | 2.807% | 25.596% |
According to BiotechBee what are the pros and cons of G1 Therapeutics for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year